Turnstone Biologics Corp. (TSBX)
After hours:
| Previous close | 2.2500 |
| Open | 2.2400 |
| Bid | 2.2200 x 100 |
| Ask | 2.2900 x 100 |
| Day's range | 2.2000 - 2.5154 |
| 52-week range | 1.6250 - 13.2000 |
| Volume | |
| Avg. volume | 164,470 |
| Market cap | 51.808M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.2400 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.67 |
Simply Wall St.Can Turnstone Biologics (NASDAQ:TSBX) Afford To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
GlobeNewswireTurnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. “We are excited about the therapeutic potential of our pipeline of
- GlobeNewswire
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the upcoming Bank of America Securities Health Care Conference on Wednesday, May
